Evidence map›Paper›PMID 33914597›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Timing of ADT in Radiotherapy of Prostate Cancer.

Stefan Höcht, Malcom Mason, Thomas Wiegel

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Stefan HöchtStefan Höcht, MD, PhD, Department of Radiotherapy, Xcare Group Practices, Saarlouis, Germany; Malcom Mason, MD, PhD, Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom; and Thomas Wiegel, MD, PhD, Department of Radiotherapy, Ulm University Hospital, Ulm, Germany.ORCID 0000-0001-6021-5984
Malcom MasonStefan Höcht, MD, PhD, Department of Radiotherapy, Xcare Group Practices, Saarlouis, Germany; Malcom Mason, MD, PhD, Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom; and Thomas Wiegel, MD, PhD, Department of Radiotherapy, Ulm University Hospital, Ulm, Germany.
Thomas WiegelStefan Höcht, MD, PhD, Department of Radiotherapy, Xcare Group Practices, Saarlouis, Germany; Malcom Mason, MD, PhD, Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom; and Thomas Wiegel, MD, PhD, Department of Radiotherapy, Ulm University Hospital, Ulm, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic NeoplasmsAndrogen AntagonistsHumansMaleAndrogen Antagonists

Identifiers

PMID33914597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.